Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer.
Adult
Aged
Aged, 80 and over
Axilla
Breast Neoplasms
/ pathology
Carcinoma, Ductal, Breast
/ secondary
Carcinoma, Lobular
/ secondary
Female
Follow-Up Studies
Humans
Intraoperative Care
Lymph Node Excision
Lymphatic Metastasis
Middle Aged
Neoplasm Invasiveness
Prognosis
Retrospective Studies
Sentinel Lymph Node
/ pathology
Sentinel Lymph Node Biopsy
Frozen section
Metastases
Sentinel lymph node
Touch imprint cytology
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
04
2020
accepted:
15
11
2020
pubmed:
30
11
2020
medline:
29
6
2021
entrez:
29
11
2020
Statut:
ppublish
Résumé
An improved procedure that allows accurate detection of negative sentinel lymph node (SLN) and of SLN macrometastases during surgery would be highly desirable in order to protect patients from further surgery and to avoid unnecessary costs. We evaluated the accuracy of an intraoperative procedure that combines touch imprint cytology (TIC) and subsequent frozen section (FS) analysis. 2276 SLNs from 1072 patients with clinical node-negative early breast cancer were evaluated during surgery using TIC. Only cytologically-positive SLN were subsequently analysed with a single FS, preserving cytologically-negative SLN for the final postoperative histological diagnosis. Sensitivity, specificity and the accuracy of this approach were analysed by comparing the results from intra- and postoperative SLN and axillary node evaluation. This intraoperative method displayed 100% specificity for SLN metastases and was significantly more sensitive for prognostically relevant macrometastases (85%) than for micrometastases (10%). Sensitivity was highest for patients with two or more positive LNs (96%) than for those with only one (72%). 98% of the patients with final pN2a-pN3a were already identified during surgery. Patients who received primary axillary lymph node dissection had significantly more frequent metastases in further LNs (44.6%). Sensitivity was highest for patients with luminal-B, HER2+ and triple negative breast cancer and for any subtype if Ki-67 > 40%. TIC and subsequent FS of cytologically-positive SLNs is highly reliable for detection of SLN macrometastases, and allows accurate identification of patients with a high risk of extended axillary involvement during surgery, as well as accurate histological diagnosis of negative SLN.
Sections du résumé
BACKGROUND
An improved procedure that allows accurate detection of negative sentinel lymph node (SLN) and of SLN macrometastases during surgery would be highly desirable in order to protect patients from further surgery and to avoid unnecessary costs. We evaluated the accuracy of an intraoperative procedure that combines touch imprint cytology (TIC) and subsequent frozen section (FS) analysis. 2276 SLNs from 1072 patients with clinical node-negative early breast cancer were evaluated during surgery using TIC. Only cytologically-positive SLN were subsequently analysed with a single FS, preserving cytologically-negative SLN for the final postoperative histological diagnosis. Sensitivity, specificity and the accuracy of this approach were analysed by comparing the results from intra- and postoperative SLN and axillary node evaluation. This intraoperative method displayed 100% specificity for SLN metastases and was significantly more sensitive for prognostically relevant macrometastases (85%) than for micrometastases (10%). Sensitivity was highest for patients with two or more positive LNs (96%) than for those with only one (72%). 98% of the patients with final pN2a-pN3a were already identified during surgery. Patients who received primary axillary lymph node dissection had significantly more frequent metastases in further LNs (44.6%). Sensitivity was highest for patients with luminal-B, HER2+ and triple negative breast cancer and for any subtype if Ki-67 > 40%. TIC and subsequent FS of cytologically-positive SLNs is highly reliable for detection of SLN macrometastases, and allows accurate identification of patients with a high risk of extended axillary involvement during surgery, as well as accurate histological diagnosis of negative SLN.
Identifiants
pubmed: 33249518
doi: 10.1007/s10585-020-10065-9
pii: 10.1007/s10585-020-10065-9
pmc: PMC7882580
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-72Références
Ann Surg. 2016 Sep;264(3):413-20
pubmed: 27513155
Mod Pathol. 2010 May;23 Suppl 2:S26-32
pubmed: 20436499
J Clin Oncol. 2014 May 1;32(13):1365-83
pubmed: 24663048
Ann Surg Oncol. 2008 May;15(5):1282-96
pubmed: 18330650
Breast Care (Basel). 2013 May;8(2):102-9
pubmed: 24000280
Breast Care (Basel). 2011;6(2):136-141
pubmed: 21633630
Histopathology. 2008 Apr;52(5):597-604
pubmed: 18370956
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
J Clin Oncol. 2017 Feb 10;35(5):561-564
pubmed: 27937089
Ann Surg Oncol. 2013 Mar;20(3):836-41
pubmed: 23010735
Acta Cytol. 2003 Nov-Dec;47(6):1028-32
pubmed: 14674073
Virchows Arch. 2012 Jan;460(1):69-76
pubmed: 22116209
Arch Pathol Lab Med. 2000 Jul;124(7):966-78
pubmed: 10888772
J Clin Oncol. 2010 Feb 10;28(5):731-7
pubmed: 20038733
Breast Cancer Res Treat. 2014 Nov;148(2):355-61
pubmed: 25318925
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Anticancer Res. 2012 Aug;32(8):3523-6
pubmed: 22843940
Breast Care (Basel). 2013 Jun;8(3):221-9
pubmed: 24415975
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
N Engl J Med. 2015 Jan 8;372(2):134-41
pubmed: 25564897
Lancet Oncol. 2014 Nov;15(12):1303-10
pubmed: 25439688
Histopathology. 1999 Jul;35(1):14-8
pubmed: 10383709
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
J Clin Oncol. 2005 Oct 20;23(30):7703-20
pubmed: 16157938
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Cancer. 2006 Jan 1;106(1):4-16
pubmed: 16329134
Histopathology. 2016 Jan;68(1):152-67
pubmed: 26768036
J Clin Oncol. 2008 Jul 20;26(21):3530-5
pubmed: 18640934
Arch Pathol Lab Med. 2016 Aug;140(8):791-8
pubmed: 27472237
Cancer. 2005 Feb 1;103(3):451-61
pubmed: 15611971
J Clin Pathol. 2004 May;57(5):467-71
pubmed: 15113852
Mod Pathol. 1999 Aug;12(8):781-5
pubmed: 10463480
Cancer. 2006 Nov 15;107(10):2328-36
pubmed: 17039501